The ITP syndrome: Pathogenic and clinical diversity

Blood

Volumn 113, Issue 26, 2009, Pages 6511-6521

  Cines, Douglas B ^a,b   Bussel, James B ^c   Liebman, Howard A ^d   Luning Prak, Eline T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AUTOANTIBODY; CORTICOSTEROID; CYCLOSPORIN; ELTROMBOPAG; FANSIDAR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN; MEASLES MUMPS RUBELLA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA; PNEUMOCOCCUS VACCINE; PREDNISONE; RHESUS D ANTIBODY; RIBAVIRIN; RITUXIMAB; VARICELLA ZOSTER VACCINE; THROMBOCYTE ANTIGEN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; CHILDHOOD DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COMMON VARIABLE IMMUNODEFICIENCY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; HELICOBACTER INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; VARICELLA ZOSTER VIRUS; ADULT; AUTOIMMUNE DISEASE; BLOOD; BLOOD DISEASE; CHILD; COMMUNICABLE DISEASE; DISEASE PREDISPOSITION; HISTOCOMPATIBILITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INCIDENCE; LYMPHOCYTE SUBPOPULATION; POSTOPERATIVE COMPLICATION; VACCINATION;

ADULT; ANTIGENS, HUMAN PLATELET; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD PLATELETS; CHILD; COMMUNICABLE DISEASES; DISEASE SUSCEPTIBILITY; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; INCIDENCE; LYMPHOCYTE SUBSETS; POSTOPERATIVE COMPLICATIONS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SELF TOLERANCE; THROMBOPOIESIS; TRANSPLANTATION IMMUNOLOGY; VACCINATION;

EID: 69249240344     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-129155     Document Type: Review

References (124)

1. He R, Reid DM, Jones CE, Shulman NR. Extracellular epitopes of platelet glycoprotein Iba reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood. 1995;86:3789-3796.
2. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4-13.
3. Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002; 100:1388-1398.
4. Satoh T, Pandey JP, Okazaki Y, et al. Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;124: 796-801. (Pubitemid 38365785)
5. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103:2645-2647. (Pubitemid 38393019)
6. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924-2930. (Pubitemid 350006946)
7. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79:310-316. (Pubitemid 47390130)
8. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev. 2003;17:69-80. (Pubitemid 36042646)
9. Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol. 2000; 79:507-513. (Pubitemid 30739546)
10. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136:309-314. (Pubitemid 46020761)
11. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374-1377. (Pubitemid 37075812)
12. Panigrahi A, Goodman N, Eisenberg R, Rickels M, Naji A, Luning Prak E. RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes. J Exp Med. 2008;205:2985-2994.
13. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
14. Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112:4003-4008.
15. France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121:e687-e692.
16. Black C, Kaye JA. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55:107-111. (Pubitemid 36110846)
17. Jadavji T, Scheifele D, Halperin S. Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J. 2003;22:119-122.
18. Ramyar A, Kalantari N. Clinical features and treatment response of immune thrombocytopenic purpura in infants. Acta Med Iran. 2007;46:510-512.
19. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876-3886. (Pubitemid 40726180)
20. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231-1240.
21. Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol. 2007; 14:557-573.
22. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124:91-96. (Pubitemid 38021628)
23. Maeda S, Ogura K, Yoshida H, et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut. 1998;42:338-343. (Pubitemid 28197021)
24. Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008;118:2939-2949.
25. Verdonck LF, van Heugten H, de Gast GC. Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. Blood. 1985;66:921-925. (Pubitemid 15242479)
26. Wright JG. Severe thrombocytopenia secondary to asymptomatic cytomegalovirus infection in an immunocompetent host. J Clin Pathol. 1992;45: 1037-1038.
27. Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol. 2008; 143:16-26.
28. Yeager AM, Zinkham WH. Varicella-associated thrombocytopenia: clues to the etiology of childhood idiopathic thrombocytopenic purpura. Johns Hopkins Med J. 1980;146:270-274.
29. Feusner JH, Slichter SJ, Harker LA. Mechanisms of thrombocytopenia in varicella. Am J Hematol. 1979;7:255-264.
30. Mayer JL, Beardsley DS. Varicella-associated thrombocytopenia: autoantibodies against platelet surface glycoprotein V. Pediatr Res. 1996;40: 615-619. (Pubitemid 26332591)
31. Welch RH. Thrombcytopenic purpura and chickenpox. Arch Dis Child. 1956;31:38-41.
32. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97: 2040-2045. (Pubitemid 34906854)
33. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282: 938-941.
34. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood. 2008;111:1344-1356. (Pubitemid 351213421)
35. Zhang W, Nardi MA, Borkowsky W, Karpatkin S. Role of molecular mimicry of hepatitis C virus (HCV) protein with platelet GPIIIa in hepatitis-C related immunologic thrombocytopenia. Blood. 2009:113:4086-4093.
36. Bordin G, Ballare M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol. 1995; 13[suppl 13]:S39-S43.
37. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005;129:818-824.
38. Sakuyara M, Murakami H, Uchiumi H, et al. Steroid-refractory chronic idiopathic thrombocytopenic purpura associated with hepatitis C virus infection. Eur J Haematol. 2002;68:48-53.
39. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227-2236.
40. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:374-379.
41. Nardi M, Karpatkin S. Antiidiotype antibody against platelet anti-gpIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients. J Exp Med. 2000;191:2093-2100. (Pubitemid 30416356)
42. Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell. 2001;106:551-561. (Pubitemid 32879317)
43. Zucker-Franklin D, Termin CS, Cooper MC. Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1). Am J Pathol. 1989;134:1295-1303. (Pubitemid 19206316)
44. Kunzi MS, Groopman JE. Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells. Blood. 1993;81:3336-3342. (Pubitemid 23172918)
45. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327:1779-1784.
46. Servais J, Nkoghe D, Schmit JC, et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:221-225. (Pubitemid 33055446)
47. Carbonara S, Fiorentino G, Serio G, et al. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect. 2001;42:251-256. (Pubitemid 32700821)
48. Walsh C, Krigel R, Lennette E, Karpatkin S. Thrombocytopenia in homosexual patients: prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1985;103:542-545.
49. Oksenhendler E, Bierling P, Chevret S, et al. Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood. 1993;82:29-32. (Pubitemid 23188742)
50. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700.
51. Duhrsen U, Augener W, Zwinger T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol. 1987; 67:235-239.
52. Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91: 1689-1692.
53. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230-239.
54. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111:1110-1116.
55. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008;93:151-152.
56. Hedge UM, Zuiable A, Ball S, Roter BL. The relative incidence of idiopathic and secondary autoimmune thrombocytopenia: a clinical and serological evaluation in 508 patients. Clin Lab Haematol. 1985;7:7-16.
57. Xiros N, Binder T, Anger B, Bohlke J, Heimpel H. Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin's disease. Eur J Haematol. 1988;40:437-441.
58. Bradley SJ, Hudson GV, Linch DC. Idiopathic thrombocytopenic purpura in Hodgkin's disease: a report of eight cases. Clin Oncol (R Coll Radiol). 1993;5:355-357. (Pubitemid 24005057)
59. Hauswirth AW, Skrabs C, Schutzinger C, et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica. 2008;93:447-450.
60. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994;84: 1620-1627.
61. Fogarty PF, Stetler-Stevenson M, Pereira A, Dunbar CE. Large granular lymphocytic proliferation- associated cyclic thrombocytopenia. Am J Hematol. 2005;79:334-336. (Pubitemid 41098852)
62. Lai DW, Loughran TP Jr, Maciejewski JP, et al. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res. 2008;32:823-827.
63. Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun. 2005;25:57-62. (Pubitemid 41008666)
64. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore). 2004; 83:254-263. (Pubitemid 38955448)
65. Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003;143:662-665.
66. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5: 156-159. (Pubitemid 43129551)
67. Zhang L, Radigan L, Salzer U, et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007;120:1178-1185.
68. Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99:1544-1551. (Pubitemid 34533024)
69. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes." Blood. 2008;112: 3303-3311.
70. Carbone J, Escudero A, Mayayo M, et al. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann N Y Acad Sci. 2005;1051:666-671. (Pubitemid 41362794)
71. Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105: 2443-2448.
72. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341-1348. (Pubitemid 27079998)
73. Heelan BT, Tormey V, Amlot P, Payne E, Mehta A, Webster AD. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol. 2002; 118:1078-1081. (Pubitemid 35025972)
74. Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129: 534-538. (Pubitemid 40769903)
75. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132:125-137.
76. Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol. 1997;19:433-437.
77. Wang WC. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol. 1988;10:330-338.
78. Scaradavou A, Bussel J. Evans syndrome: results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol. 1995;17: 290-295.
79. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol. 2004;77:303-310.
80. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol. 1996;93:1-5.
81. Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2- glycoprotein I antibodies in complex with beta2- glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54:2558-2567.
82. Pennings MT, Derksen RH, Urbanus RT, Tekelenburg WL, Hemrika W, de Groot PG. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost. 2007;5:1538-1544.
83. Pennings MT, Derksen RH, van Lummel M, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2007;5:369-377.
84. Vallar L, Regnault V, Latger-Cannard V, Lecompte T. Beta2-glycoprotein I binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost. 2001;85: 314-319.
85. Lipp E, von Felten A, Sax H, Muller D, Berchtold P. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol. 1998;60:283-288.
86. Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol. 2005;128:366-372.
87. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84:4203-4208.
88. Ziakas PD, Poulou LS, Giannouli S, Tzioufas AG, Voulgarelis M. Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse. Ann Rheum Dis. 2007;66:130-131.
89. Panzer S, Penner E, Graninger W, Schulz E, Smolen JS. Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years. Am J Hematol. 1989; 32:100-103.
90. Anderson MJ, Peebles CL, McMillan R, Curd JG. Fluorescent antinuclear antibodies and anti- SSA/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythematosus. Ann Intern Med. 1985;103:548-550.
91. Nakamura M, Tanaka Y, Satoh T, et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford). 2006;45:150-156.
92. Kuwana M, Okazaki Y, Kajihara M, et al. Autoantibody to cMpl (thrombopoietin receptor) in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2148-2159.
93. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1988;108:703-706.
94. Nossent JC, Swaak AJG. Prevalence and signifi- cance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med. 1991;80:605-612.
95. Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1990;112:674-677.
96. Hall S, McCormick JL Jr, Griepp PR, Michet CJ, McKenna CH. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med. 1985;102:325-328.
97. Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29:75-83.
98. Minchinton RM, Waters AH. Autoimmune thrombocytopenia and neutropenia after bone marrow transplantation. Blood. 1985;66:752-753.
99. Friend PJ, McCarthy LJ, Filo RS, et al. Transmission of idiopathic (autoimmune) thrombocytopenic purpura by liver transplantation. N Engl J Med. 1990;323:807-811.
100. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88: 3-46.
101. Provan D, Newland A, Bolton-Maggs P, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120:574-596.
102. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med. 2006;3: e24.
103. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-2393.
104. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377-2383.
105. Ogawara H, Handa H, Morita K, et al. High Th1/ Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;71: 283-288.
106. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis M, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood. 2002;100:1774-1779.
107. Sukati H, Watson HG, Urbaniak SJ, Barker RN. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood. 2007;109: 4528-4538.
108. Catani L, Fagioli ME, Tazzari PL, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol. 2006; 34:879-887.
109. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87:4245-4254.
110. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood. 2005;105:215-218. (Pubitemid 40053085)
111. Olsson B, Andersson P-O, Jernas M, Jacobsson S, Carlsson LMS, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9: 1123-1124. (Pubitemid 37173694)
112. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008; 112:1078-1084.
113. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104:956-960. (Pubitemid 39038013)
114. Fogarty PF, Rick ME, Zeng W, Risitano AM, Dunbar CE, Bussel JB. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol. 2003;133:461-466. (Pubitemid 37046973)
115. Cines DB. ITP: time to "bug off"? Blood. 2007; 110:3818-3819.
116. Semple JW, Aslam R, Kim M, Speck ER, Freedman J. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood. 2007;109:4803-4805. (Pubitemid 46827774)
117. Ioachimescu AG, Makdissi A, Lichtin A, Zimmerman RS. Thyroid disease in patients with idiopathic thrombocytopenia: a cohort study. Thyroid. 2007;17:1137-1142. (Pubitemid 350207755)
118. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33-40.
119. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364-1369. (Pubitemid 38168649)
120. Houwerzijl EJ, Blom NR, van der Want JJL, et al. Ultrastructural study shows morphological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500-506.
121. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004; 76:205-213.
122. Norvell A, Mandik L, Monroe JG. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J Immunol. 1995;154:4404-4413.
123. Nemazee D. Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol. 2006;6:728-740. (Pubitemid 44453459)
124. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995;182:1265-1273.